VIVEX Biologics Company Profile

Background

VIVEX Biologics is a biotechnology company specializing in regenerative medicine solutions, focusing on the development, processing, storage, and distribution of human tissue allografts and medical devices. Established in 1970 as The University of Miami Tissue Bank, the company has over five decades of experience in tissue banking and regenerative medicine. VIVEX's mission is to provide advanced allografts that aid patients suffering from musculoskeletal injuries, wounds, and burned skin, thereby improving patient outcomes and quality of life. The company's vision centers on advancing regenerative medicine through innovative tissue-based therapies.

Key Strategic Focus

VIVEX Biologics' strategic focus encompasses:

Core Objectives: Developing innovative allografts, enhancing manufacturing capabilities, and expanding sales and marketing efforts.

Areas of Specialization: Regenerative medicine solutions, particularly in orthopedic, spine, and wound care therapies.

Key Technologies Utilized: Integrity Processing™, a proprietary methodology that protects tissue from harmful agents, preserving the natural state of allografts to support regenerative potential.

Primary Markets Targeted: Healthcare providers, including hospitals and medical professionals, focusing on patients with musculoskeletal injuries, chronic wounds, and burned skin.

Financials and Funding

VIVEX Biologics is a privately held company with an estimated annual revenue of $54.6 million and approximately 282 employees. The company has secured total funding of $14.2 million. Specific details regarding recent funding rounds, notable investors, and intended utilization of capital are not publicly disclosed.

Pipeline Development

VIVEX Biologics is actively involved in the development of several pipeline candidates:

VIA Disc NP™: An allogeneic disc tissue therapy designed to supplement degenerated intervertebral discs. The company has completed subject enrollment for its ASCEND Trial evaluating VIA Disc NP for symptomatic disc degeneration.

Cygnus®: An amnion-based skin substitute for wound care, with a real-world evidence study demonstrating superior or similar outcomes compared to other treatments.

VIA Form+: A product for lumbar interbody fusion, with a peer-reviewed publication demonstrating long-term fusion outcomes.

These products are in various stages of clinical trials and product development, targeting conditions such as degenerative disc disease, chronic wounds, and musculoskeletal injuries.

Technological Platform and Innovation

VIVEX Biologics distinguishes itself through:

Proprietary Technologies: Integrity Processing™, which maintains the natural state of tissue, preserving inherent characteristics to support regenerative potential.

Significant Scientific Methods: Utilization of advanced tissue processing techniques to ensure the safety and efficacy of allografts.

AI-Driven Capabilities: While specific AI-driven capabilities are not detailed, the company's focus on innovation suggests potential integration of advanced technologies in product development.

Leadership Team

VIVEX Biologics' leadership team includes:

John A. McCallum: Executive Chairman

Barry Salzman: Co-President and Chief Operating Officer

Reinaldo (Rey) Pascual: Co-President and General Counsel

Vanessa Baron: Vice President of Research and Development

Erin Chance: Deputy General Counsel & Chief Compliance Officer

Brian Fromhold: Senior Vice President of Finance

Timothy Ganey, Ph.D.: Chief Technology Officer

Santiago Osorio, CTBS: Vice President of Operations

Michele Pablos, MBA: Vice President of Ortho & Fusion Therapies/Strategic Accounts

H. Thomas Temple, MD: Chief Medical Officer

Laura Trivette: Vice President of Health Policy and Reimbursement

Each member brings extensive experience in their respective fields, contributing to the company's growth and innovation.

Leadership Changes

Recent significant changes include:

January 2022: Reinaldo (Rey) Pascual became Co-President and General Counsel.

January 2022: Barry Salzman was appointed Co-President and Chief Operating Officer.

2019: Erin Chance joined as Deputy General Counsel & Chief Compliance Officer.

2019: Vanessa Baron joined as Vice President of Research and Development.

These appointments reflect the company's commitment to strengthening its leadership team to drive strategic initiatives.

Competitor Profile

Market Insights and Dynamics

The regenerative medicine market, particularly in tissue allografts, is experiencing growth due to increasing incidences of musculoskeletal injuries, chronic wounds, and skin burns. Advancements in tissue processing technologies and a focus on patient outcomes are key drivers in this sector.

Competitor Analysis

VIVEX Biologics faces competition from companies such as Ossium Health, which focuses on bioengineering and cell therapies. Additionally, companies like Hikma are also active in this market segment.